Shenzhen Huixin Biomedical Technology
Developing automated exosome purification systems for early cancer diagnosis and treatment applications.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | CNY100m | Series A | |
| Total Funding | 000k | ||
Related Content
Shenzhen Huixin Biomedical Technology Co., Ltd. is a biotechnology company that develops automated systems for exosome purification, with applications in early disease detection, diagnostics, and biomedical research. The company's focus is on improving the efficiency and consistency of isolating exosomes—small extracellular vesicles found in biological fluids that carry molecular information such as proteins and nucleic acids.
HuixinBio’s purification platforms are designed to support workflows in clinical laboratories, academic research, and pharmaceutical development. These systems use microfluidic and automation technologies to streamline the exosome isolation process, aiming to provide high-purity samples while reducing manual handling and processing time.
The company's technology supports non-invasive diagnostic approaches such as liquid biopsy, which is used in areas like early cancer screening and biomarker discovery. By enabling more consistent and scalable exosome extraction, HuixinBio contributes tools that may assist in research and development for precision medicine and disease monitoring.
In addition to product development, Huixin Biomedical is engaged in partnerships and collaborations with institutions and researchers in the field of exosome science. The company continues to expand its portfolio to meet the needs of evolving biomedical and clinical applications.
Keywords:
Huixin Biomedical, HuixinBio, exosome purification, automated exosome systems, liquid biopsy, microfluidic technology, early disease detection, cancer diagnostics, biomedical research, precision medicine, extracellular vesicles, diagnostic tools, biotechnology company, Shenzhen biotech, exosome isolation.